Clinical Trial Update: Sapropterin Expanded Access Program

View source ↗

Summary

Sapropterin (Kuvan) has been approved for marketing for phenylketonuria under an expanded access program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• KUVAN (Sapropterin dihydrochloride)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria | Status: APPROVED_FOR_MARKETING